-
Indian hit movie 'Dhurandhar' breaks Bollywood records
-
Australia PM welcomes Iran ceasefire, says Trump threats not 'appropriate'
-
Nigeria sweats in heatwave as Iran war drives up costs to stay cool
-
'Pinprick of light': Artemis crew witnesses meteorite impacts on Moon
-
German factory orders rise in February but energy shock looms
-
China says investigating 'malicious' cyberbullying of teen diving star
-
North Korea fires two rounds of ballistic missiles: Seoul military
-
Taiwan opposition leader says China visit to sow 'seeds of peace'
-
Jet fuel supplies to take 'months' to recover from war disruption: IATA
-
How did Pakistan broker a temporary truce between Iran and the US?
-
North Korea fires multiple ballistic missiles in two rounds: Seoul military
-
Rockets comeback sinks Phoenix on Durant return
-
'Ketamine Queen' to be sentenced over Matthew Perry death
-
Vietnam's To Lam bets big on building blitz
-
Sooryavanshi, 15, hailed as 'amazing, fearless' after acing Bumrah test
-
Pakistan to host US-Iran ceasefire talks Friday
-
Middle East war: ceasefire reactions
-
North Korea fires multiple ballistic missiles towards East Sea
-
Both sides claim victory after US, Iran agree to 11th-hour truce
-
Unbeaten legend Winx's $7 million foal retires without racing
-
Trump to AFP: Iran deal 'total and complete victory' for US
-
Solar push helps Pakistan temper Gulf energy shock
-
Crude prices plunge, stocks surge as US and Iran agree ceasefire
-
Wave of nostalgia as 2000s TV makes a comeback
-
Iraqi armed group releases US journalist
-
Forest's Igor Jesus eyes Europa League 'dream', Villa brace for Bologna in quarters
-
In-demand prop De Lutiis rebuffs Ireland to commit to Australia
-
US, Iran agree to 11th-hour truce after Trump apocalyptic threats
-
The Metals Royalty Company Inc. to Commence Trading on the Nasdaq Capital Market Under the Symbol "TMCR"
-
Mosaic Announces Idling Of Araxá And Patrocínio Facilities And Pursuit Of Sale Of Araxá Assets
-
Marijuana Rescheduling Countdown: Why the "Order of Operations" and Todd Blanche's Appointment Define the Path to Schedule III
-
New Birth Injury Resource Center Launches as Data Shows Thousands of Newborns Face Preventable Complications Each Year
-
Kingfisher Appoints Sharon G.K. Singh to Board of Directors
-
Rad Source Technologies Activates a Wealth of Peer-Reviewed Data with Bioz Badges to Strengthen Customer Use-Case Visibility
-
Tocvan Announces Addition of Second Drill Rig and Accelerates High-Priority Drill Targets at Flagship Gran Pilar Gold-Silver Project
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 08
-
Trump suspends Iran bombing for two weeks, after apocalyptic threats
-
Latest Anthropic AI model finds cracks in software defenses
-
McIlroy chases Masters repeat at lightning-fast Augusta
-
Arsenal's Raya hailed as 'world's best keeper' after denying Sporting
-
Bayern's Kompany praises 'special' Neuer display in win at Real Madrid
-
Diaz, Kane give Bayern vital Champions League win at Real
-
Havertz strikes late as Arsenal steal Champions League advantage against Sporting
-
Pakistan makes last-minute bid to avert Trump threat to destroy Iran
-
Artemis II crew basks in glow of lunar flyby en route to Earth
-
Global stocks mostly fall ahead of Trump's deadline for Iran
-
Trump weighs plea for Iran deadline extension
-
Artemis and ISS astronauts share celestial call
-
Former Romania coach Lucescu dies aged 80
-
'Nice to get a 2nd chance': Slot tips Liverpool to bounce back against PSG
Adding peanuts to young children's diet can help avoid allergy: study
Including peanuts in children's diets early in life could help stave off allergies against the legume, which can be fatal and affect swathes of youngsters globally, according to a new study Friday.
Researchers found that introducing peanut products to babies and infants, and gradually increasing exposure, led to greater tolerance for the common allergen.
The peer-reviewed study, published in The Lancet, involved 146 peanut-allergic children aged between zero and three over two-and-a-half years.
Of the group, 96 were given peanut protein powder every day, with the dose increasing progressively to the equivalent of six peanuts. The other children received a placebo of oat flour.
Twenty of the children who received peanut powder showed allergy remission, meaning no allergic reaction occurred six months after the therapy ended.
One child in the placebo group showed remission.
Six months after the treatment, the children in remission could tolerate a dose equivalent to 16 peanuts.
An additional 20 children who received peanut powder were considered 'desensitised', meaning they had a higher allergic threshold but were not considered in remission.
These children could tolerate a dose equivalent to between six and 12 peanuts six months after the treatment ended.
The youngest children in the study experienced remission the most often, and the best results were in those under 12 months.
"Very early interventions may provide the best opportunity to achieve remission", said co-author Stacie Jones.
- 'Considerable burden' -
Peanut allergies affect two percent of children in Western countries, according to the study, and can last a lifetime.
Affected children must avoid eating peanuts and have self-injectable adrenaline available to fight allergic shocks, which can be fatal if they are accidentally exposed.
Exposure can even occur when a child hugs someone who has just consumed peanuts.
"There are no treatment options, resulting in a considerable burden on allergic children and their caregivers to avoid accidental exposure," said co-author Wesley Burks.
"In severe cases, this can restrict peanut-allergic children's freedoms, particularly when it comes to navigating daycare or schools and public spaces where access to a safe diet is in jeopardy," he added.
Previous studies have produced similar results but the length of the latest studies makes it unique.
Although it provided important results, it may not reflect the behaviour of the children's bodies in real-world conditions.
The study was conducted under close medical supervision, and adrenaline injections were administered on 21 children during the trial.
Y.Nakamura--AMWN